Pure MHC & Catalent Sign Cancer Development Deal
Pure MHC, LLC and Catalent Pharma Solutions recently announced the signing of a product development agreement. Under the terms of the agreement, Catalent will develop a humanized version of Pure MHC’s proprietary RL21A antibody and engineer a cell line to express the antibody using Catalent’s GPEx technology. Catalent will subsequently produce purified monoclonal antibodies to support Pure MHC’s preclinical development in preparation for clinical trials with humanized RL21A for the treatment of cancer. GPEx technology is used to generate mammalian cells with high yields and stability, helping to speed drugs to clinic.
“We are confident that our partnership with Catalent will result in the development of the enhanced antibodies necessary to help get RL21A into the clinic more quickly”, said Thomas Harlan, CEO of Pure MHC. “Our ultimate goal for this technology is to one day provide cancer patients with a treatment option that is safer and more effective than those available today.”
“We are delighted to again demonstrate how GPEx technology, together with Catalent’s development and manufacturing expertise, can support development of novel therapies and enable companies such as Pure MHC to validate their unique target screening methodology,” said Jonathan Arnold, VP, General Manager of Catalent’s Advanced Delivery Technologies business.
Pure MHC has developed a suite of MHC/ligand targets that recognize cancerous cells in addition to producing monoclonal antibodies for these distinct MHC/ligand cancer targets. Antibodies such as RL21A distinguish primary cancers from healthy tissue and, in animal models, have been shown to arrest tumor development.
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing worldwide clinical and commercial supply capabilities for drugs, biologics, and consumer health products. For more information, visit www.catalent.com.
Pure MHC is an immunology company focused on MHC-based diagnostics and therapeutics that was formed from innovative technologies developed in two Emergent Technologies portfolio companies, Pure Protein, LLC and Receptor Logic, LLC, to provide a novel solution for the treatment of infectious diseases and cancers. For more information, visit www.puremhc.com.
Total Page Views: 1126
